Clinical Study of SUPRA (Sildenafil) in the Treatment of Erectile Dysfunction in Yemen

Prof. Dr.H.O.Kadi

Abstract:

Erectile dysfunction (ED) is a widespread, age-related problem,which affects 52% of men between 40 and 70 years of age. Itclassified as psychogenic, organic or mixed.Therefore,adequatetreatment of ED is needed and the most convenient and the simplestway is oral drug therapy. Sildenafil citrate is the first oral agentapproved by the U.S. Food and Drug Administration for thetreatment of erectile dysfunction (ED). The aim of this study is toevaluate the clinical effect of Supra (sildenafil) manufacturer, ShibaPhrama Ind. Co.in treatment of erectile dysfunction in Yemen.Efficacy was assessed using the International Index of ErectileFunction (IIEF), a 15-item, self-administered questionnaire. Themaximum total IIEF score is 85 and the minimum IIEF score is 5,with higher scores indicating greater erectile function. After 4-6weeks of Supra (sildenafil) treatment, there was significantimprovementerectile function scores (27.7 +3.4) compared withthe baseline (16.1 +4.6). Also, there were marked improvements inthe ability to achieve and maintain an erection, with the mean scoresfor IIEF Q3 and Q4 significantly higher (4.8 +0.4 for each one)compared with the baseline scores (P<0.001). The mean of orgasmic_and sexual desire was significantly higher (9.5 +0.9 and 9.3 +0.9respectively) compared with the baseline scores (6.1 +1.3 and 4.9+1.8, respectively).The mean of successful intercourse attempts wassignificantly higher with the mean scores (13.1 +2.0) compared withthe baseline (6.7 +2.5), (P 0.001). The overall satisfaction wasmarked significantly higher (9.6 +1.0) compared with the baselinescores (5.1 +1.3). The present study comes to the conclusion thatSupra (sildenafil) iseffective device in the treatment of patientswith erectile dysfunction.